Whistleblower case alleging kickback for promotion of Novartis MS drug Gilenya dismissed Ruchika Sharma14 Sept 2022 2:30 PM ISTNovartis moved to dismiss, arguing that Camburn still had not offered enough detail to support his claim of a fraudulent scheme.
Cosentyx shows clinically meaningful symptom improvements in patients with painful skin condition in pivotal Phase III trials: Novartis Ruchika Sharma12 Sept 2022 3:00 PM ISTHidradenitis Suppurativa is a chronic, inflammatory, debilitating skin condition with systemic comorbidities that has a profoundly negative effect on...
Novartis plans to shut down Sandoz North Carolina plant by 2023 end Ruchika Sharma12 Sept 2022 12:24 PM ISTZurich: Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on...
Novartis Kisqali adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer Ruchika Sharma11 Sept 2022 3:18 PM ISTBasel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program,...
Setback: HC rejects Sun Pharma plea against Hetero alleging trademark infringement of cancer drug Letroz Farhat Nasim6 Sept 2022 5:33 PM ISTNew Delhi: Holding that when the name is derived or coined from the name of the principal ingredient being used in the manufacture of the drug, no...
Novartis Gets CDSCO Panel Nod To Study Ianalumab Dr. Divya Colin4 Sept 2022 11:17 AM ISTNew Delhi: In a significant development, drug major Novartis has got a green signal from the Subject Expert Committee (SEC) functional under the...
Novartis: Scemblix approved in the EU for adults with chronic myeloid leukemia Kajal Rajput29 Aug 2022 3:03 PM ISTBasel: Novartis today announced that the European Commission (EC) has approved Scemblix (asciminib) for the treatment of adult patients with...
Novartis Sandoz division to go independent Ruchika Sharma25 Aug 2022 2:33 PM ISTThe standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in...
Post USFDA nod, Bluebird Bio USD 2.8 million gene therapy becomes most expensive drug Ruchika Sharma19 Aug 2022 4:32 PM ISTBluebird has pitched Zynteglo as a potential one-time treatment that could do away with the need for transfusions, resulting in savings for patients...
Novartis Gets CDSCO Panel Nod To Study Crizanlizumab Dr. Divya Colin18 Aug 2022 6:00 PM ISTNew Delhi: Pharmaceutical major Novartis has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drugs Standard...
Novartis Lung cancer drug Canakinumab fails in Phase 3 trial Ruchika Sharma17 Aug 2022 4:15 PM ISTBasel: Novartis has recently announced that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of...
Zolgensma gene therapy caused two fatalities from liver failure, reports Novartis Ruchika Sharma14 Aug 2022 2:00 PM ISTBasel: Novartis AG on Thursday reported two patient fatalities due to acute liver failure following treatment with Zolgensma gene therapy used to...
